H5移動(dòng)端
手機(jī)訪問(wèn)更快捷
微信公眾號(hào)
手機(jī)簽到贏積分
微信小程序
玩轉(zhuǎn)移動(dòng)新?tīng)I(yíng)銷
? |
?
|
? |
聯(lián)系方式
加關(guān)注5
云試劑直營(yíng)渠道![]() 資料通過(guò)認(rèn)證
保證金未繳納
|
中文名: | 帕納替尼;Ponatinib (AP24534) |
中文別名: | AP 24534; AP-24534;3-(2-咪唑并[1,2-b]噠嗪-3-乙炔基)-4-甲基-N-[4-[(4-甲基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]苯甲酰胺; |
英文名稱: | AP24534(Ponatinib) |
英文別名: | AP 24534; AP24534; AP-24534;3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
CAS No.: | 943319-70-8 |
分子式: | C29H27F3N6O |
分子量: | 532.56 |
性狀: | 屬性溶解性Soluble in DMSO (100 mM), ethanol (50 mM), methanol, and water (<1 mg/ml) at 25 °C.存貯條件儲(chǔ)存溫度-20°C熔點(diǎn)>160 °C描述產(chǎn)品介紹Ponatinib (AP24534)是一種新型有效的作用于Abl, PDGFRα, VEGFR2, FGFR1和Src的多靶點(diǎn)抑制劑, IC50分別為0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM和5.4 nM。用途A Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor生化機(jī)理AP 24534 is a small molecule, multi-target kinase inhibitor known to potently inhibit Bcr-Abl (the fusion protein of Bcr and c-Abl), Flk-1(VEGFR2) and FGFR. It also exhibits inhibitory activity against PDGFRα, c-Src and c-Kit. AP 24534 inhibits the proliferation of mutant FLT3-positive cells (IC50 of 13 nM), which inhibits mutant FLT3 phosphorylation (IC50 of 1 nM) and the proliferation of Bcr-Abl1 T315I-positive Ba/F3 cells with an IC50 of 8 nM.包裝P127550-10mg,P127550-50mg,P127550-250mg in glass bottle |
儲(chǔ)存: | 儲(chǔ)存溫度-20°C |
安全術(shù)語(yǔ): | |
風(fēng)險(xiǎn)術(shù)語(yǔ): | |
危險(xiǎn)品標(biāo)志: | |
危險(xiǎn)品運(yùn)輸編號(hào): | |
用途: | AP24534 is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN. |